Sbc Medical Group Holdings Incorporated · NASDAQ:SBC
Sbc Medical — Q1 2025 Earnings Presentation
18 slides from Sbc Medical's earnings presentation, May 2025
Slide 1: 2025 First Quarter Financial Highlights
2025 First Quarter Financial Highlights May 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements & Legal DisclaimerThis presentation contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements are not historical facts; they reflect our current expectations, estimates and projection
Slide 3: 2025Q1 Franchise Clinics Performance Highlights
2025Q1 Franchise Clinics Performance Highlights • We believe Strategic pricing management is driving strong customer growth, particularly in aesthetic dermatology Franchise Clinics Key Figures（25Q1） Number of Franchise clinics¹ Repeat Rate² ³ ⁴ Total Revenue ¹ ⁵ ⁷ ⁸ at the end of Mar 25 251 clinics
Slide 4: 2025Q1 Financial Performance Highlights
2025Q1 Financial Performance Highlights • SBC demonstrated impressive bottom line growth SBC Medical Group Holdings Key Financials (25Q1) Total Revenues EBITDA¹ EBITDA Margin² $47 M $25 M 52 % (YoY (14)%) (YoY (3)%) (YoY +6pt) Net Income ROE³ (Annualized) Basic EPS⁴ attributable to SBC Medical Group
Slide 5: Income Statement (Consolidated)
Income Statement (Consolidated) • Income from operations was maintained through expense reductions, while declines in revenue and cost of sales due to the termination of the staffing business and the deconsolidation of SNA and Kijimadaira¹ Income Statement²（25Q1） (mm US$) 25Q1 % YoY 24Q1 1 Total rev
Slide 6: Revenue Grew After Adjusting for One-time Business Impact
Revenue Grew After Adjusting for One-time Business Impact • Revenue¹ grew YoY after adjusting for the impact of the termination of the staffing business termination and the deconsolidation of SNA and Kijimadaira (mm US$) (2.9) (5.6) +2.2 +2.0 (1.4) +1.3 54.8 +1.1 (1.4) +0.6 48.6 47.3 46.4 24Q1 Decon
Slide 7: EBITDA Remained In-line with Previous Year
EBITDA Remained In-line with Previous Year • EBITDA¹ ² remained in line with the previous year, reflecting the decline in Revenue, Adjusted CGS, and Operating Expenses-Others resulting from the termination of the staffing business and the deconsolidation of SNA and Kijimadaira. +0.7 (mm US$) +1.6 +0
Slide 8: Robust Balance Sheet Positioned for Growth
Robust Balance Sheet Positioned for Growth • SBC’s balance sheet is strong with ample cash and borrowing capacity Key Balance Sheet Figures (as of March 31, 2025) Selected items from Balance Sheet Mar 31, Dec 31, (mm US$) 2025 Change 2024 Total assets 285 +19 266 US$132mn 0.05x Total current assets
Slide 9: Share Buyback
Share Buyback • Based on the view that the current share price undervalues the company’s performance and growth, a USD5mm million share buyback was decided, and the planned Bitcoin purchase announced in February 2025 was canceled • The policy to consider additional share liquidity in line with fundi
Slide 10: Appendix
Appendix SBC Medical Group Holdings, Inc. 1 0)
Slide 11: Income Statement (Consolidated)
Income Statement (Consolidated) Income Statement Operating Expenses 25Q1 % QoQ % YoY 24Q4 24Q1 25Q1 % QoQ % YoY 24Q4 24Q1 (mm US$) (mm US$) Total revenues 47 +7% (14)% 44 55 Total operating expenses 14 (54)% (10)% 29 15 Franchising Revenue 16 +1% +4% 16 15 Salaries and welfare 6 +15% (1)% 6 7 Procur
Slide 12: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) Mar 31, Dec 31, Mar 31, Dec 31, (mm US$) 2025 Change 2024 (mm US$) 2025 Change 2024 Total assets 285 +19 266 Total liabilities 58 (13) 71 Total current assets 215 +31 184 Total current liabilities 48 (13) 61 Cash and cash equivalent 132 +7 125 Accounts payable 18 +4 14 N
Slide 13: Cash Flows (Consolidated)
Cash Flows (Consolidated) 25Q1 24Q1 (mm US$) %YoY Net cash provided by operating activities 2 (48)% 4 Net cash provided by (used in) investing activities (1) +71% (3) Net cash provided by financing activities (0) (597)% (0) Effect of changes in foreign currency exchange rate 6 n.m. (7) Net change in
Slide 14: 2025Q1 Revenue Growth (vs 24Q4)
2025Q1 Revenue Growth（vs 24Q4） • Revenue growth rebounded from Q4 2024 +4.1 (mm US$) +0.7 （1.0） +3.8 +0.1 +0.3 47.3 47.7 (0.8) +0.1 44.4 43.6 24Q4 Deconsolidation 24Q4 Franchising Procurement Management Rental services Others 25Q1 FX 25Q1 of SNA and Adjusted Revenue Services Revenue adjusted FX Kiji
Slide 15: 2025Q1 EBITDA Growth (vs 24Q4)
2025Q1 EBITDA Growth(vs24Q4) • EBITDA¹ remained in-line with previous year +0.2 (mm US$) +0.5 +1.0 +0.5 (0.8) +2.9 24.8 25.0 20.7 24Q4 Revenue Adjusted CGS Saiaries Consulting and Operating 25Q1 FX 25Q1 and welfare professional Expenses-Others adjusted FX service fees ¹ EBITDA = Income from operatio
Slide 16: Reconciliation Table on Non-GAAP Financials
Reconciliation Table on Non-GAAP Financials （mm US$） 25Q1 24Q1 24Q4 (A) Total Revenues 47 55 44 (B) Income from operations 24 24 5 (C) Depreciation and 1 1 1 amortization expense 0 0 15 (D) Impairment loss (E) =(B)+(C) +(D) EBITDA 25 25 21 (F) =(E)／(A) EBITDA Margin 52% 46% 47% 16
Slide 17: Disclaimer
Disclaimer Non-GAAP Financial Measures This presentation may reference certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are provided in the appendix to this presentation and are available on our investor relations website. No Offer o
Slide 18: Thank you
Thank you SBC Medical Group Holdings / ir@sbc-holdings.com ICR, LLC / US Investor Contact / +1 (646) 277 1200 /William.Zima@icrinc.com
SBC Medical Group Holdings — Q1 2025 Earnings Presentation on 6ix